Huaan Securities released a research report on April 22 stating that it gave Antu Biotech (603658.SH) a purchase rating. The main reasons for the rating include: 1) the light emitting business continued to grow steadily, with a growth rate of about 24.88% in 2023; 2) R&D investment increased, and gross margin increased as the share of self-produced products increased. (Mainichi Keizai Shimbun)
华安证券4月22日发布研报称，给予安图生物（603658.SH）买入评级。评级理由主要包括：1）发光业务仍保持稳健增长，2023年增速约24.88%；2）研发费用投入增加，毛利率随自产产品占比提高而提升。（每日经济新闻）
Huaan Securities released a research report on April 22 stating that it gave Antu Biotech (603658.SH) a purchase rating. The main reasons for the rating include: 1) the light emitting business continued to grow steadily, with a growth rate of about 24.88%
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.